Eli Lilly and Co at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 03:30PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning. I'd like to welcome Eli Lilly to Cowen's 42nd Annual Healthcare Conference. We're very, very pleased to have Lilly back with us again this year. Let me say that Cowen is recommending Eli Lilly stock because we see above-average growth driven by differentiated new products, which has been a feature of Lilly for virtually 10 years, if not more. So exciting situation that we think investors should be participating in.

So representing the company is Anat Ashkenazi, who is the CFO of the company. So Anat, thank you so much for being with us today.

Questions and Answers:

Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

I'd like to start out with one of the most exciting developments that will occur in 2022, and that is tirzepatide. And I'm curious, is Lilly ready to launch immediately post-approval? Or will it depend on what the label says and some time will be needed to train the sales
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot